IHCH-3185 is an orally active Class I HDAC inhibitor (HDAC1 IC50=102.9 nM) and A2AR antagonist (A2AR Ki=7.6 nM). It reverses immune gene silencing by inducing histone acetylation and blocks adenosine signaling, thus lifting T cell suppression. IHCH-3185 exhibits antiproliferative activity and induces cell cycle arrest while significantly improving the tumor microenvironment. It reduces the proportion of regulatory T cells, increases the CD8+/Treg ratio, and upregulates key factors like H2-K1, Cxcl9, and Cxcl10 expression. Demonstrating substantial antitumor potential in CT26 and MC38 mouse tumor models, IHCH-3185 is suitable for cancer research.

HDAC1:102.9 nM